Prescription drug usage as measure of comorbidity resolution after bariatric surgery: a population-based cohort study
Background Obesity is a chronic and progressive disease associated with significant morbidity, mortality, and health-care costs. Bariatric surgery is the most effective intervention for sustainable weight loss and resolution of obesity-related comorbidities. Studies examining comorbidity resolution...
Gespeichert in:
| Veröffentlicht in: | Surgical endoscopy 2023-11, Vol.37 (11), p.8601-8610 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8610 |
|---|---|
| container_issue | 11 |
| container_start_page | 8601 |
| container_title | Surgical endoscopy |
| container_volume | 37 |
| creator | Wu, Ted Chia Hao He, Wenjing Dharmasena, Isuru Prior, Heather J. Vergis, Ashley Hardy, Krista |
| description | Background
Obesity is a chronic and progressive disease associated with significant morbidity, mortality, and health-care costs. Bariatric surgery is the most effective intervention for sustainable weight loss and resolution of obesity-related comorbidities. Studies examining comorbidity resolution largely rely on individual self-reported outcomes and electronic record reviews. We present a population-based study looking at prescription medication utilization before and after bariatric surgery as a measure of comorbidity resolution.
Methods
All patients enrolled in the Center for Metabolic and Bariatric Surgery who underwent either gastric bypass or sleeve gastrectomy between 2013 and 2019 in Manitoba were included. Demographic information, follow up, and outpatient prescription dispensation data were obtained from the
Manitoba Population Research Data Repository
housed at the Manitoba Centre for Health Policy for 5 years pre- and post-surgery.
Results
A total of 1184 patients were included. Antidepressants and selective serotonin reuptake inhibitors were the most commonly prescribed classes, and along with thyroid medication, utilization remained stable after bariatric surgery. Proton pump inhibitors and opioid class drugs increased at 1 year after surgery then returned to baseline. Glucose and lipid-lowering medications, including statins, biguanides, sulfonylureas, and insulin, were decreased. Antihypertensives, including ACE inhibitors, calcium channel blockers, angiotensin receptors blockers, thiazides, and beta blockers, similarly decreased.
Conclusion
This is the first Canadian study employing a provincial-wide prescription database to measure long-term comorbidity resolution after bariatric surgery. The use of administrative data eliminates potential biases and inaccuracies in follow up and self-reported outcomes. Consistent with the literature, prescriptions for the treatment of metabolic syndrome all decreased and were sustained at long-term follow up. Further studies are needed to delineate the effects of altered pharmaceutical utilization on patient quality of life and health-care expenditures. |
| doi_str_mv | 10.1007/s00464-023-10294-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2842452080</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2842452080</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-1da1fb2231b2c6cca06debc818aea04e78c463473bc5434e40d2be87bd65291b3</originalsourceid><addsrcrecordid>eNp90ctu1DAUBmALFdFp4QW6QJa6YWM4viRxukMVUKRKsIC15cvJNFUyDna8mLfH0ylF6qIrW_J3flv-Cbng8JEDdJ8ygGoVAyEZB9Er1rwiG66kYEJwfUI20EtgouvVKTnL-R6q73nzhpzKrm7apt-Q8jNh9mlc1jHuaEhlS0u2W6Q20xltLglpHKiPc0xuDOO6p3UgTuXB22HFRJ1No13T6GnlW0z7K2rpEpcy2YNizmYMNeIuppXmtYT9W_J6sFPGd4_rOfn99cuv6xt2--Pb9-vPt8xL0a6MB8sHJ4TkTvjWewttQOc11xYtKOy0V61UnXS-UVKhgiAc6s6FthE9d_KcfDjmLin-KZhXM4_Z4zTZHcaSjdBKqEaAhkovn9H7WNKuvq4qrQDaRjdViaPyKeaccDBLGmeb9oaDOZRijqWYWop5KMUcht4_Rhc3Y3ga-ddCBfIIcj3a1R_8f_cLsX8BG56Ziw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2884006585</pqid></control><display><type>article</type><title>Prescription drug usage as measure of comorbidity resolution after bariatric surgery: a population-based cohort study</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Wu, Ted Chia Hao ; He, Wenjing ; Dharmasena, Isuru ; Prior, Heather J. ; Vergis, Ashley ; Hardy, Krista</creator><creatorcontrib>Wu, Ted Chia Hao ; He, Wenjing ; Dharmasena, Isuru ; Prior, Heather J. ; Vergis, Ashley ; Hardy, Krista</creatorcontrib><description>Background
Obesity is a chronic and progressive disease associated with significant morbidity, mortality, and health-care costs. Bariatric surgery is the most effective intervention for sustainable weight loss and resolution of obesity-related comorbidities. Studies examining comorbidity resolution largely rely on individual self-reported outcomes and electronic record reviews. We present a population-based study looking at prescription medication utilization before and after bariatric surgery as a measure of comorbidity resolution.
Methods
All patients enrolled in the Center for Metabolic and Bariatric Surgery who underwent either gastric bypass or sleeve gastrectomy between 2013 and 2019 in Manitoba were included. Demographic information, follow up, and outpatient prescription dispensation data were obtained from the
Manitoba Population Research Data Repository
housed at the Manitoba Centre for Health Policy for 5 years pre- and post-surgery.
Results
A total of 1184 patients were included. Antidepressants and selective serotonin reuptake inhibitors were the most commonly prescribed classes, and along with thyroid medication, utilization remained stable after bariatric surgery. Proton pump inhibitors and opioid class drugs increased at 1 year after surgery then returned to baseline. Glucose and lipid-lowering medications, including statins, biguanides, sulfonylureas, and insulin, were decreased. Antihypertensives, including ACE inhibitors, calcium channel blockers, angiotensin receptors blockers, thiazides, and beta blockers, similarly decreased.
Conclusion
This is the first Canadian study employing a provincial-wide prescription database to measure long-term comorbidity resolution after bariatric surgery. The use of administrative data eliminates potential biases and inaccuracies in follow up and self-reported outcomes. Consistent with the literature, prescriptions for the treatment of metabolic syndrome all decreased and were sustained at long-term follow up. Further studies are needed to delineate the effects of altered pharmaceutical utilization on patient quality of life and health-care expenditures.</description><identifier>ISSN: 0930-2794</identifier><identifier>EISSN: 1432-2218</identifier><identifier>DOI: 10.1007/s00464-023-10294-5</identifier><identifier>PMID: 37491659</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>2023 SAGES Oral ; Abdominal Surgery ; Bariatric Surgery ; Canada ; Cohort analysis ; Cohort Studies ; Comorbidity ; Gastrectomy ; Gastric Bypass ; Gastroenterology ; Gastrointestinal surgery ; Gynecology ; Hepatology ; Humans ; Medicine ; Medicine & Public Health ; Metabolism ; Obesity - complications ; Obesity - epidemiology ; Obesity - surgery ; Obesity, Morbid - surgery ; Population-based studies ; Prescription Drugs ; Prescriptions ; Proctology ; Quality of Life ; Retrospective Studies ; Surgery ; Treatment Outcome ; Weight control</subject><ispartof>Surgical endoscopy, 2023-11, Vol.37 (11), p.8601-8610</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-1da1fb2231b2c6cca06debc818aea04e78c463473bc5434e40d2be87bd65291b3</cites><orcidid>0009-0004-0220-9788</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00464-023-10294-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00464-023-10294-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37491659$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Ted Chia Hao</creatorcontrib><creatorcontrib>He, Wenjing</creatorcontrib><creatorcontrib>Dharmasena, Isuru</creatorcontrib><creatorcontrib>Prior, Heather J.</creatorcontrib><creatorcontrib>Vergis, Ashley</creatorcontrib><creatorcontrib>Hardy, Krista</creatorcontrib><title>Prescription drug usage as measure of comorbidity resolution after bariatric surgery: a population-based cohort study</title><title>Surgical endoscopy</title><addtitle>Surg Endosc</addtitle><addtitle>Surg Endosc</addtitle><description>Background
Obesity is a chronic and progressive disease associated with significant morbidity, mortality, and health-care costs. Bariatric surgery is the most effective intervention for sustainable weight loss and resolution of obesity-related comorbidities. Studies examining comorbidity resolution largely rely on individual self-reported outcomes and electronic record reviews. We present a population-based study looking at prescription medication utilization before and after bariatric surgery as a measure of comorbidity resolution.
Methods
All patients enrolled in the Center for Metabolic and Bariatric Surgery who underwent either gastric bypass or sleeve gastrectomy between 2013 and 2019 in Manitoba were included. Demographic information, follow up, and outpatient prescription dispensation data were obtained from the
Manitoba Population Research Data Repository
housed at the Manitoba Centre for Health Policy for 5 years pre- and post-surgery.
Results
A total of 1184 patients were included. Antidepressants and selective serotonin reuptake inhibitors were the most commonly prescribed classes, and along with thyroid medication, utilization remained stable after bariatric surgery. Proton pump inhibitors and opioid class drugs increased at 1 year after surgery then returned to baseline. Glucose and lipid-lowering medications, including statins, biguanides, sulfonylureas, and insulin, were decreased. Antihypertensives, including ACE inhibitors, calcium channel blockers, angiotensin receptors blockers, thiazides, and beta blockers, similarly decreased.
Conclusion
This is the first Canadian study employing a provincial-wide prescription database to measure long-term comorbidity resolution after bariatric surgery. The use of administrative data eliminates potential biases and inaccuracies in follow up and self-reported outcomes. Consistent with the literature, prescriptions for the treatment of metabolic syndrome all decreased and were sustained at long-term follow up. Further studies are needed to delineate the effects of altered pharmaceutical utilization on patient quality of life and health-care expenditures.</description><subject>2023 SAGES Oral</subject><subject>Abdominal Surgery</subject><subject>Bariatric Surgery</subject><subject>Canada</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Comorbidity</subject><subject>Gastrectomy</subject><subject>Gastric Bypass</subject><subject>Gastroenterology</subject><subject>Gastrointestinal surgery</subject><subject>Gynecology</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Obesity - complications</subject><subject>Obesity - epidemiology</subject><subject>Obesity - surgery</subject><subject>Obesity, Morbid - surgery</subject><subject>Population-based studies</subject><subject>Prescription Drugs</subject><subject>Prescriptions</subject><subject>Proctology</subject><subject>Quality of Life</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Treatment Outcome</subject><subject>Weight control</subject><issn>0930-2794</issn><issn>1432-2218</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp90ctu1DAUBmALFdFp4QW6QJa6YWM4viRxukMVUKRKsIC15cvJNFUyDna8mLfH0ylF6qIrW_J3flv-Cbng8JEDdJ8ygGoVAyEZB9Er1rwiG66kYEJwfUI20EtgouvVKTnL-R6q73nzhpzKrm7apt-Q8jNh9mlc1jHuaEhlS0u2W6Q20xltLglpHKiPc0xuDOO6p3UgTuXB22HFRJ1No13T6GnlW0z7K2rpEpcy2YNizmYMNeIuppXmtYT9W_J6sFPGd4_rOfn99cuv6xt2--Pb9-vPt8xL0a6MB8sHJ4TkTvjWewttQOc11xYtKOy0V61UnXS-UVKhgiAc6s6FthE9d_KcfDjmLin-KZhXM4_Z4zTZHcaSjdBKqEaAhkovn9H7WNKuvq4qrQDaRjdViaPyKeaccDBLGmeb9oaDOZRijqWYWop5KMUcht4_Rhc3Y3ga-ddCBfIIcj3a1R_8f_cLsX8BG56Ziw</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Wu, Ted Chia Hao</creator><creator>He, Wenjing</creator><creator>Dharmasena, Isuru</creator><creator>Prior, Heather J.</creator><creator>Vergis, Ashley</creator><creator>Hardy, Krista</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0004-0220-9788</orcidid></search><sort><creationdate>20231101</creationdate><title>Prescription drug usage as measure of comorbidity resolution after bariatric surgery: a population-based cohort study</title><author>Wu, Ted Chia Hao ; He, Wenjing ; Dharmasena, Isuru ; Prior, Heather J. ; Vergis, Ashley ; Hardy, Krista</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-1da1fb2231b2c6cca06debc818aea04e78c463473bc5434e40d2be87bd65291b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>2023 SAGES Oral</topic><topic>Abdominal Surgery</topic><topic>Bariatric Surgery</topic><topic>Canada</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Comorbidity</topic><topic>Gastrectomy</topic><topic>Gastric Bypass</topic><topic>Gastroenterology</topic><topic>Gastrointestinal surgery</topic><topic>Gynecology</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Obesity - complications</topic><topic>Obesity - epidemiology</topic><topic>Obesity - surgery</topic><topic>Obesity, Morbid - surgery</topic><topic>Population-based studies</topic><topic>Prescription Drugs</topic><topic>Prescriptions</topic><topic>Proctology</topic><topic>Quality of Life</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Treatment Outcome</topic><topic>Weight control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Ted Chia Hao</creatorcontrib><creatorcontrib>He, Wenjing</creatorcontrib><creatorcontrib>Dharmasena, Isuru</creatorcontrib><creatorcontrib>Prior, Heather J.</creatorcontrib><creatorcontrib>Vergis, Ashley</creatorcontrib><creatorcontrib>Hardy, Krista</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Surgical endoscopy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Ted Chia Hao</au><au>He, Wenjing</au><au>Dharmasena, Isuru</au><au>Prior, Heather J.</au><au>Vergis, Ashley</au><au>Hardy, Krista</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prescription drug usage as measure of comorbidity resolution after bariatric surgery: a population-based cohort study</atitle><jtitle>Surgical endoscopy</jtitle><stitle>Surg Endosc</stitle><addtitle>Surg Endosc</addtitle><date>2023-11-01</date><risdate>2023</risdate><volume>37</volume><issue>11</issue><spage>8601</spage><epage>8610</epage><pages>8601-8610</pages><issn>0930-2794</issn><eissn>1432-2218</eissn><abstract>Background
Obesity is a chronic and progressive disease associated with significant morbidity, mortality, and health-care costs. Bariatric surgery is the most effective intervention for sustainable weight loss and resolution of obesity-related comorbidities. Studies examining comorbidity resolution largely rely on individual self-reported outcomes and electronic record reviews. We present a population-based study looking at prescription medication utilization before and after bariatric surgery as a measure of comorbidity resolution.
Methods
All patients enrolled in the Center for Metabolic and Bariatric Surgery who underwent either gastric bypass or sleeve gastrectomy between 2013 and 2019 in Manitoba were included. Demographic information, follow up, and outpatient prescription dispensation data were obtained from the
Manitoba Population Research Data Repository
housed at the Manitoba Centre for Health Policy for 5 years pre- and post-surgery.
Results
A total of 1184 patients were included. Antidepressants and selective serotonin reuptake inhibitors were the most commonly prescribed classes, and along with thyroid medication, utilization remained stable after bariatric surgery. Proton pump inhibitors and opioid class drugs increased at 1 year after surgery then returned to baseline. Glucose and lipid-lowering medications, including statins, biguanides, sulfonylureas, and insulin, were decreased. Antihypertensives, including ACE inhibitors, calcium channel blockers, angiotensin receptors blockers, thiazides, and beta blockers, similarly decreased.
Conclusion
This is the first Canadian study employing a provincial-wide prescription database to measure long-term comorbidity resolution after bariatric surgery. The use of administrative data eliminates potential biases and inaccuracies in follow up and self-reported outcomes. Consistent with the literature, prescriptions for the treatment of metabolic syndrome all decreased and were sustained at long-term follow up. Further studies are needed to delineate the effects of altered pharmaceutical utilization on patient quality of life and health-care expenditures.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>37491659</pmid><doi>10.1007/s00464-023-10294-5</doi><tpages>10</tpages><orcidid>https://orcid.org/0009-0004-0220-9788</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0930-2794 |
| ispartof | Surgical endoscopy, 2023-11, Vol.37 (11), p.8601-8610 |
| issn | 0930-2794 1432-2218 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2842452080 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | 2023 SAGES Oral Abdominal Surgery Bariatric Surgery Canada Cohort analysis Cohort Studies Comorbidity Gastrectomy Gastric Bypass Gastroenterology Gastrointestinal surgery Gynecology Hepatology Humans Medicine Medicine & Public Health Metabolism Obesity - complications Obesity - epidemiology Obesity - surgery Obesity, Morbid - surgery Population-based studies Prescription Drugs Prescriptions Proctology Quality of Life Retrospective Studies Surgery Treatment Outcome Weight control |
| title | Prescription drug usage as measure of comorbidity resolution after bariatric surgery: a population-based cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T19%3A14%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prescription%20drug%20usage%20as%20measure%20of%20comorbidity%20resolution%20after%20bariatric%20surgery:%20a%20population-based%20cohort%20study&rft.jtitle=Surgical%20endoscopy&rft.au=Wu,%20Ted%20Chia%20Hao&rft.date=2023-11-01&rft.volume=37&rft.issue=11&rft.spage=8601&rft.epage=8610&rft.pages=8601-8610&rft.issn=0930-2794&rft.eissn=1432-2218&rft_id=info:doi/10.1007/s00464-023-10294-5&rft_dat=%3Cproquest_cross%3E2842452080%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2884006585&rft_id=info:pmid/37491659&rfr_iscdi=true |